CDK4/6 inhibitors in combination with phosphatidylinositol 3‐kinase (PI3K)/mTOR or TGFβ receptor type I (TGFβ‐RI) inhibitors have confirmed efficacy in preclinical pancreatic cancer models.21, 22. Here, MTOR is linked to familial pancreatic carcinoma.